Filing Analysis
RenovoRx, Inc. has successfully regained compliance with the Nasdaq Minimum Bid Price Requirement. The company's common stock maintained a closing bid price of $1.00 or greater for ten consecutive business days, ending August 19, 2026.
📋 Key Facts
- The company was previously non-compliant with Nasdaq Listing Rule 5550(a)(2) as of December 31, 2025.
- Non-compliance was due to the closing bid price being below $1.00 for 30 consecutive business days.
- Compliance was regained after the stock closed at or above $1.00 for ten consecutive business days (August 6, 2026, through August 19, 2026).
- Nasdaq has officially considered the matter closed.
This is an amendment to a previously filed 8-K (filed May 12, 2026) intended solely to correct a broken or incorrect hyperlink in the original filing's exhibits. The company also notes it has issued a press release regarding its quarterly financial results for the period ending June 30, 2026.
📋 Key Facts
- Filing is an amendment (8-K/A) to the Original 8-K filed on May 12, 2026.
- Purpose of filing: Correcting a hyperlink to Exhibit 99.1 in the original report.
- The company issued financial results for the quarter ended June 30, 2026, via press release on August 12, 2026.
- RenovoRx is an emerging growth company.
RenovoRx, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing serves as a formal notification of the release of quarterly earnings via press release.
📋 Key Facts
- Report date: August 12, 2026
- Reporting period: Quarter ended June 30, 2026
- The company is an emerging growth company as defined by the SEC.
- Financial results were released via press release (Exhibit 99.1).
RenovoRx, Inc. announced its upcoming participation in a JonesTrading key opinion leader webinar scheduled for August 13, 2026. The presentation will focus on pancreatic cancer and the company's proprietary technology platform.
📋 Key Facts
- Company to participate in a JonesTrading KOL webinar on August 13, 2026.
- Webinar topic: Pancreatic cancer and RenovoRx's technology platform.
- Filing date: August 4, 2026.
RenovoRx, Inc. has failed to regain compliance with Nasdaq's $1.00 minimum bid price requirement by the initial June 30, 2026 deadline. The company has been granted a second 180-day compliance period extending until December 28, 2026.
🚩 Red Flags
- Delisting notice/Non-compliance with minimum bid price requirement
- Repeated failure to maintain Nasdaq listing standards (Second Compliance Period)
- Risk of transition from Nasdaq Capital Market to over-the-counter (OTC) markets if compliance is not met.
📋 Key Facts
- The company failed to meet the $1.00 minimum bid price requirement by the initial June 30, 2026 deadline.
- Nasdaq has granted a second compliance period of 180 days, expiring December 28, 2026.
- Compliance requires the closing bid price to be at least $1.00 for 10 consecutive business days.
- Failure to meet requirements by the new deadline will result in delisting proceedings and potential appeal to a Hearings Panel.
RenovoRx, Inc. held its 2026 annual meeting of stockholders on June 30, 2026. Shareholders approved the election of six directors, an amendment to the 2021 Omnibus Equity Incentive Plan, and the ratification of Frank, Rimerman + Co. LLP as independent auditors.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on June 30, 2026.
- Six directors were elected: Shaun R. Bagai, Ramtin Agah, Kirsten Angela Macfarlane, Laurence J. Marton, Una S. Ryan, and Robert J. Spiegel.
- Stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan to add 2,000,000 shares (approx. 4.4% of total outstanding shares) to the pool.
- Frank, Rimerman + Co. LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Quorum was established with approximately 22,825,465 shares of voting stock present.
RenovoRx, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release attached as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the quarter ended March 31, 2026.
- The report was filed on May 14, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release containing the full financial details was included as Exhibit 99.1.
RenovoRx, Inc. announced its fiscal year 2025 financial results and provided updates on its clinical trial and commercialization strategy. The disclosure was made via a press release on March 30, 2026.
📋 Key Facts
- Reported financial results for the fiscal year ended December 31, 2025
- Provided updates on the company's clinical trial progress
- Provided updates on the company's commercialization strategy
- The filing was made under Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events)
RenovoRx, Inc. has appointed Dr. Ramtin Agah, its current Chief Medical Officer and Chairman, to the newly created role of Executive Chairman. The transition involves a formal employment agreement with a $450,000 base salary for a minimum 30-hour work week, replacing a consulting agreement from 2018.
📋 Key Facts
- Dr. Ramtin Agah was appointed to the newly created position of Executive Chairman effective February 27, 2026.
- Dr. Agah will receive an annualized base salary of $450,000 based on a minimum of 30 hours worked per week.
- The executive is eligible for an annual discretionary bonus of up to 40% of his base salary.
- The new 'Agah Offer Letter' replaces a Consulting Agreement dated January 1, 2018.
- An existing Amended and Restated Change in Control and Severance Agreement from November 10, 2025, remains in effect.
RenovoRx, Inc. closed a $10 million private placement offering (PIPE) of common stock and warrants involving 15 investors, including five company insiders. The offering includes unique 'Milestone Warrants' that expire early if the company achieves $1.5 million in quarterly product sales revenue.
🚩 Red Flags
- Related-party transaction: Five insiders participated in the private placement.
- Significant potential dilution: Over 7.5 million shares issuable upon exercise of warrants.
- Liquidated damages clause: Penalty of 2.0% per month if registration is delayed.
- Low share price: Offering price of ~$0.94 indicates the company is trading in penny stock territory.
📋 Key Facts
- Gross proceeds of approximately $10 million before fees of 5.5% plus $50,000 in expenses.
- Issued 8,438,790 shares of common stock and 2,200,000 pre-funded warrants.
- Issued 5,319,392 'Milestone Warrants' with exercise prices of $1.751 (Institutional) and $1.9326 (Insiders).
- Five insiders (directors, officers, or employees) participated in the offering at a higher price ($1.0288 vs $0.938) to comply with Nasdaq rules.
- Milestone Warrants expire 30 days after the company reports $1.5 million in product sales revenue for any calendar quarter.
- Company must file a resale registration statement within 30 days or face liquidated damages of up to 10% of the subscription amount.
RenovoRx, Inc. announced the resignation of its Principal Accounting Officer (Ronald B. Kocak) and the appointment of a consultant, Mark Voll, as interim Chief Financial Officer effective February 4, 2026.
🚩 Red Flags
- Sudden departure of the Principal Accounting Officer (PAO) can sometimes precede financial reporting delays or restatements, though no restatement is explicitly mentioned here.
- The CFO role is being filled by an independent contractor on a consulting basis rather than a permanent hire, suggesting potential instability in the finance department.
- High turnover/change in key financial leadership (PAO and CFO) within a single week.
📋 Key Facts
- Ronald B. Kocak resigned as Principal Accounting Officer on February 3, 2026; he remains as VP and Controller.
- Mark Voll appointed as CFO/Principal Financial and Accounting Officer on February 4, 2026.
- Mr. Voll is being engaged via a Consulting Agreement as an independent contractor rather than a full-time employee.
- Compensation for Mr. Voll includes $250 per hour (50% cash / 50% RSUs) and an initial grant of 60,000 unvested RSUs.
- The resignation of Mr. Kocak was voluntary and did not constitute 'Good Reason' or a 'Qualified Termination'.
RenovoRx, Inc. received a deficiency notice from Nasdaq on December 31, 2025, due to its common stock failing to maintain the $1.00 minimum bid price requirement. The company has an initial 180-day period to regain compliance by June 30, 2026.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential requirement for a reverse stock split to meet market value standards if second compliance period is needed
- Persistent low share price (32+ consecutive days below $1.00)
📋 Key Facts
- Deficiency notice received from Nasdaq on December 31, 2025.
- Failure to comply with Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price.
- The deficiency is based on the closing bid price being below $1.00 for 32 consecutive business days prior to the notice.
- Initial compliance period granted until June 30, 2026.
- To regain compliance, the stock must close at or above $1.00 for at least ten consecutive business days before the deadline.
RenovoRx, Inc. entered into an 'at-the-market' (ATM) sales agreement with JonesTrading Institutional Services LLC to facilitate the potential issuance and sale of up to $3,723,029 in common stock.
🚩 Red Flags
- Potential dilution of existing shareholders through the ATM offering.
- The use of an ATM facility often indicates a need for immediate working capital in micro-cap biotech firms.
📋 Key Facts
- Entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC on November 14, 2025.
- The agreement allows for the issuance and sale of up to $3,723,029 in aggregate principal amount of common stock.
- Sales will be conducted via 'at-the-market' (ATM) methods or negotiated transactions.
- Agent commission is set at up to 3.0% of the gross sales price.
- The company filed a new S-3 shelf registration statement on November 14, 2025, to extend its ability to sell shares for an additional 180 days beyond the current expiration.
RenovoRx, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025 and provided updates regarding clinical trial and commercialization strategies.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and strategic updates.
- Updates include clinical trial progress and commercialization strategy details.
RenovoRx, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025, and provided updates regarding clinical trial and commercialization strategies.
📋 Key Facts
- Reporting date: August 14, 2025
- Period covered: Quarter ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and clinical/commercialization updates.
- Company is an emerging growth company.
RenovoRx, Inc. held its 2025 annual meeting of stockholders on June 24, 2025. The company successfully elected its board of directors and approved amendments to its equity incentive plan and the ratification of its independent auditor.
📋 Key Facts
- Annual Meeting held on June 24, 2025.
- Quorum was established with approximately 20,086,518 shares of Voting Stock present (approx. 55% of outstanding shares as of Record Date).
- All seven director nominees were elected for one-year terms.
- Stockholders approved an increase in the 2021 Omnibus Equity Incentive Plan by adding 913,794 shares (2.5% of total issued and outstanding).
- The 'evergreen' provision for the equity plan was increased from 3% to 5% annually.
- Stockholders ratified Frank, Rimerman + Co. LLP as independent auditors for the fiscal year ending December 31, 2025.
RenovoRx, Inc. filed an 8-K to announce its quarterly financial results for the period ended March 31, 2025, and provided clinical trial updates.
📋 Key Facts
- Financial results announced for the quarter ended March 31, 2025.
- Clinical trial updates were included in the same press release (Exhibit 99.1).
- The company is classified as an 'emerging growth company'.
RenovoRx, Inc. filed an 8-K to announce its full-year financial results for the period ending December 31, 2024, and provided clinical trial updates via a press release.
📋 Key Facts
- Report date: April 1, 2025
- Reporting Period: Fiscal year ended December 31, 2024
- The filing includes an announcement of financial results (Item 2.02).
- The filing includes updates regarding the Company's clinical trials (Item 8.01).
RenovoRx, Inc. entered into an underwriting agreement to conduct a firm commitment public offering of 11,523,810 shares of common stock at $1.05 per share. The offering aims to raise approximately $10.9 million in net proceeds.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 11 million new shares.
- Offering price ($1.05) is relatively low, typical of micro-cap capital raises used to fund operations.
- Warrant issuance (576,191 shares) creates potential future dilution.
📋 Key Facts
- Offering size: 11,523,810 shares of common stock.
- Offering price: $1.05 per share.
- Expected net proceeds: Approximately $10.9 million.
- Underwriter: Titan Partners Group LLC (division of American Capital Partners, LLC).
- Warrants issued: 576,191 shares at an exercise price of $1.21 per share, exercisable in 6 months.
- Standstill provision: 45-day prohibition on issuing new securities.
RenovoRx, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024.
📋 Key Facts
- The filing was made on November 14, 2024.
- The report pertains to the quarterly results ending September 30, 2024.
- The company is an emerging growth company.
- Financial results were released via a press release (Exhibit 99.1).
RenovoRx, Inc. issued a press release announcing increased production of its FDA-Cleared RenovoCath® Delivery System and an expanded relationship with manufacturing partner Medical Murray, Inc.
📋 Key Facts
- Announced increased production of the FDA-Cleared RenovoCath® Delivery System.
- Expanded partnership/relationship with manufacturing partner Medical Murray, Inc.
- Filing date: September 25, 2024.
RenovoRx, Inc. announced the resignation of its independent auditor, Baker Tilly US, LLP, effective August 13, 2024, following the filing of the Q2 2024 10-Q. The company has appointed Frank, Rimerman + Co. LLP as its new independent public accounting firm.
🚩 Red Flags
- Auditor change: Sudden resignation of an auditor can sometimes signal underlying disputes, though the company explicitly denies any disagreement in this filing.
📋 Key Facts
- Baker Tilly US, LLP resigned effective August 13, 2024.
- The resignation followed the filing of the Quarterly Report for the period ended June 30, 2024.
- Frank, Rimerman + Co. LLP has been engaged to audit fiscal year 2024 and review Q3 2024 financial statements.
- The company stated there were no disagreements with the predecessor auditor regarding accounting principles or reporting issues.
RenovoRx, Inc. announced the entry into a Change in Control and Severance Agreement with its Vice President, Controller, and Principal Accounting Officer, Ronald B. Kocak. The filing also reports the results of the company's 2024 annual meeting of stockholders where several directors were elected.
🚩 Red Flags
- Departure/Severance agreement for the Principal Accounting Officer (CAO) can sometimes signal internal friction or upcoming changes in financial leadership, though no restatement was noted here.
📋 Key Facts
- Ronald B. Kocak (VP, Controller, and Principal Accounting Officer) entered into a Change in Control and Severance Agreement on June 6, 2024.
- Severance terms include 50% of annual base compensation and target bonus for non-cause terminations by the company or good reason termination by the executive.
- Change in control provisions include 100% of annual base compensation, 12 months of COBRA, and 100% vesting acceleration of equity awards if terminated within one year of a change in control.
- The 2024 Annual Meeting of Stockholders was held on June 6, 2024, with approximately 10.1 million shares represented (a quorum).
- Six directors were elected to one-year terms: Shaun R. Bagai, Ramtin Agah, M.D., Kirsten Angela Macfarlane, Laurence J. Marton, M.D., Una S. Ryan, O.B.E., Ph.D., D.Sc., and Robert J. Spiegel, M.D., FACP.
RenovoRx, Inc. announced the resignation of its independent auditor, Baker Tilly US, LLP, effective after the filing of the Q2 2024 10-Q in August 2024. The company is currently interviewing replacement firms.
🚩 Red Flags
- Auditor change (Baker Tilly US, LLP resigning)
- Existing 'going concern' language in previous audit reports
- Disclosed material weakness in internal control over financial reporting
- Executive salary increases and bonuses following recent cost-cutting measures
📋 Key Facts
- Baker Tilly US, LLP (BT) resigned as the independent registered public accounting firm on April 29, 2024.
- The resignation becomes effective after the filing of the Form 10-Q for the quarter ended June 30, 2024 (expected August 2024).
- BT's previous reports included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
- The company disclosed material weaknesses in internal control over financial reporting for fiscal years 2022 and 2023.
- No disagreements regarding accounting principles or auditing scope were reported between the company and BT prior to resignation.
RenovoRx, Inc. has received notification from Nasdaq confirming it is back in compliance with all listing requirements, specifically resolving a previous deficiency regarding the $2.5 million minimum stockholders' equity requirement.
🚩 Red Flags
- Previous non-compliance with minimum stockholders' equity requirements (remedied but indicates past financial distress).
📋 Key Facts
- Nasdaq notified the company on April 17, 2024, of compliance with all applicable listing criteria for The Nasdaq Capital Market.
- The company has remedied its previously disclosed listing deficiency regarding the $2.5 million minimum stockholders' equity requirement.
- The scheduled hearing before the Nasdaq Hearings Panel has been cancelled due to the resolution of the deficiency.
RenovoRx, Inc. reports that it has regained compliance with Nasdaq's minimum stockholders' equity requirement following an $11.1 million private placement closed on April 11, 2024. The company is currently awaiting formal confirmation from Nasdaq regarding its compliance status.
🚩 Red Flags
- Previous non-compliance with Nasdaq minimum equity requirements.
- Risk of future delisting if subsequent periodic reports do not evidence continued compliance.
📋 Key Facts
- The company was previously notified of potential delisting due to non-compliance with Nasdaq Listing Rule 5550(b)(1) (minimum $2.5 million equity requirement).
- Closed an at-market private placement of common stock and warrants on April 11, 2024.
- The financing generated gross proceeds of $11.1 million.
- Company believes it has regained compliance with the Equity Requirement as of the date of the report (April 16, 2024).
- Awaiting formal confirmation from Nasdaq Staff regarding compliance status.
RenovoRx, Inc. closed a private placement offering on April 11, 2024, raising approximately $11.1 million in gross proceeds to be used for working capital. The offering included common stock and multiple series of warrants issued to investors and the placement agent.
🚩 Red Flags
- Significant dilution: The issuance of over 19 million total warrant shares (Series A, B, Pre-funded, and PA) represents substantial potential future dilution for existing shareholders.
- High cost of capital: Placement agent fees represent approximately 11.5% of the gross proceeds ($1.33M / $11.1M).
- Warrant overhang: The inclusion of multiple warrant tiers (Series A, B, and Pre-funded) is a common characteristic of distressed or highly dilutive micro-cap financing.
📋 Key Facts
- Gross proceeds from the offering: ~$11.1 million; Net proceeds expected: ~$9.6 million.
- Issued 6,960,864 shares of common stock.
- Issued a Pre-Funded Warrant for 951,500 shares at $0.0001 per share.
- Issued Series A Warrants for 7,912,364 shares at $1.22 per share (5-year term).
- Issued Series B Warrants for 3,956,182 shares at $1.22 per share (2-year term).
- Issued Placement Agent (PA) Warrants for 701,243 shares at $1.69 per share.
- Newbridge Securities Corporation served as the placement agent, receiving ~$1.28 million in commissions and $50,000 in expenses.
RenovoRx, Inc. entered into definitive subscription agreements for a private placement offering to approximately 170 accredited investors. The offering includes common stock and significant warrant coverage (150%) via Series A and Series B warrants.
🚩 Red Flags
- Significant dilution risk due to high warrant coverage (150%).
- Potential for downward pressure on stock price from the upcoming Resale Registration Statement.
- High selling commission (up to 12%) paid to placement agent.
- Warrant exercise prices ($1.22) are close to/below current implied pricing, indicating potential immediate dilution.
📋 Key Facts
- Offering expected to close on April 11, 2024.
- Total shares of Common Stock to be sold: 7,912,364.
- Issuance of five-year Series A Warrants for up to 7,912,364 shares at $1.22 exercise price.
- Issuance of two-year Series B Warrants for up to 3,956,182 shares at $1.22 exercise price.
- Total warrant coverage is 150% of the common stock being sold.
- Purchase price per share and related warrants: $1.4075.
- Placement Agent (Newbridge Securities Corporation) to receive a 12% selling commission (3% for Company-introduced investors).
- Company to issue PA Warrants to Placement Agent equal to 9.0% of Shares sold at $1.22 exercise price.
RenovoRx, Inc. announced the appointment of Leesa Gentry as Chief Clinical Officer on February 22, 2024, following her previous role as Senior Vice President of Clinical Operations. The filing details her amended and restated offer letter including salary and equity compensation.
📋 Key Facts
- Leesa Gentry appointed as Chief Clinical Officer effective March 1, 2024.
- Annual base salary set at $325,000.
- Target annual incentive bonus of up to 35% of base salary.
- Grant of 190,000 stock options with an exercise price of $1.69 per share.
- Options vest over four years in monthly increments (1/48th per month) starting March 1, 2024.
RenovoRx received notice from Nasdaq that it has failed to meet the minimum stockholders' equity requirement and will face delisting proceedings unless a hearing is requested. The company also announced the resignation of its COO and the appointment of a new Chief Clinical Officer.
🚩 Red Flags
- Delisting notice from Nasdaq due to failure to meet minimum stockholders' equity requirements.
- Failure of previous extension (which expired February 19, 2024) to regain compliance.
- Departure of the Chief Operating Officer (COO).
📋 Key Facts
- Nasdaq issued a notice on February 21, 2024, stating the company failed to meet the Minimum Stockholders' Equity Requirement.
- The company's stockholders' equity was $1.188 million as of June 30, 2023, below the required $2.5 million.
- Company plans to request a hearing before the Nasdaq Hearing Panel to stay delisting proceedings.
- On January 29, 2024, the company closed a private placement resulting in gross proceeds of approximately $6.1 million.
- COO Angela Gill Nelms resigned effective March 1, 2024, for personal reasons.
- Leesa Gentry has been appointed Chief Clinical Officer, effective March 1, 2024.
RenovoRx, Inc. announced the immediate resignation of its Chief Financial Officer, James Ahlers, effective February 5, 2024. The company has appointed current Controller Ronald B. Kocak to serve as Vice President, Controller and Principal Accounting Officer.
🚩 Red Flags
- Sudden departure of the Chief Financial Officer (CFO) is often viewed as a risk factor for micro-cap companies, even when stated to be for personal reasons.
- The replacement is an internal promotion from Controller rather than an external veteran CFO, which may suggest limited immediate resources or a desire for continuity during transition.
📋 Key Facts
- James Ahlers resigned as CFO on February 5, 2024, for personal reasons; the company states there was no disagreement regarding operations or policies.
- Ronald B. Kocak, CPA, CGMA, appointed as VP, Controller and Principal Accounting Officer effective February 8, 2024.
- Kocak's compensation includes an annual base salary of $235,000 and a bonus target of up to 35% of base salary.
- Kocak was granted stock options for 15,000 shares at an exercise price of $1.56 per share, vesting over four years with a double-trigger provision upon Change in Control.
RenovoRx, Inc. closed a private placement offering on January 26, 2024, raising approximately $6.1 million through the sale of common stock and warrants at a 10% discount to market price. Simultaneously, the company implemented significant cash conservation measures, including a 25% salary reduction for named executive officers.
🚩 Red Flags
- Significant dilution via the issuance of over 6.1 million shares and 6.1 million warrants.
- Cash conservation measures (25% executive salary cuts) indicate liquidity/burn rate concerns.
- Issuance of employee bonuses in the form of 10-year options instead of cash, signaling a lack of liquid capital.
- The offering required an extension from January 15 to January 26 to meet minimum subscription requirements.
📋 Key Facts
- Raised aggregate gross proceeds of $6,111,695 via private placement.
- Sold 6,133,414 shares and an equal number of warrants at $0.99 per share/warrant.
- The offering price represented a 10% discount to the VWAP of $1.10 on January 23, 2024.
- Five insiders (officers, directors, employees, or consultants) paid a higher price of $1.22 per share/warrant.
- The company will file a resale registration statement within 30 days of closing.
- Named executive officers (Ramtin Agah, Shaun Bagai, and Angela Gill Nelms) received a 25% reduction in annual base salaries to conserve cash.
RenovoRx, Inc. announced the passing of David Diamond on December 26, 2023. Mr. Diamond was a long-standing member of the Board of Directors and held several key leadership roles within the board committees.
🚩 Red Flags
- Loss of key governance leadership (Audit Committee Chair and Lead Independent Director) creates temporary vacancy in oversight roles.
📋 Key Facts
- David Diamond passed away on December 26, 2023.
- Mr. Diamond had served on the Board since May 2021.
- He served as Chair of the Audit Committee and a member of the Compensation Committee.
- He held the position of Lead Independent Director.
- The Board intends to seek a replacement for his vacated roles.